Treatment options for XLH are currently expanding beyond phosphate and vitamin D. A novel treatment with burosumab, a FGF-23 antibody, has shown superiority to conventional treatments regarding improvement of rickets and linear growth (38). This evidence concerns the gene FGF23 and X-linked hypophosphatemia.